Mainz Biomed B.V. (MYNZ)
USD 3.37
(1.2%)
USD 3.37
(1.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.4 Million USD | -23.87% |
| 2022 | 20.24 Million USD | 101.59% |
| 2021 | 10.04 Million USD | 1391.35% |
| 2020 | 673.27 Thousand USD | -5.96% |
| 2019 | 715.95 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 15.4 Million USD | -13.95% |
| 2023 Q2 | 19.3 Million USD | -1.19% |
| 2023 Q1 | 19.53 Million USD | -3.47% |
| 2023 Q3 | 17.9 Million USD | -7.24% |
| 2023 FY | 15.4 Million USD | -23.87% |
| 2022 Q2 | 27.61 Million USD | 0.0% |
| 2022 Q4 | 20.24 Million USD | 0.0% |
| 2022 FY | 20.24 Million USD | 101.59% |
| 2021 Q1 | 2.51 Million USD | 272.84% |
| 2021 FY | 10.04 Million USD | 1391.35% |
| 2021 Q3 | 2.51 Million USD | 241.77% |
| 2021 Q4 | 10.04 Million USD | 300.0% |
| 2021 Q2 | 734.47 Thousand USD | -70.74% |
| 2020 FY | 673.27 Thousand USD | -5.96% |
| 2020 Q4 | 673.27 Thousand USD | 300.0% |
| 2020 Q3 | 168.31 Thousand USD | 0.0% |
| 2020 Q2 | 168.31 Thousand USD | 0.0% |
| 2020 Q1 | 168.31 Thousand USD | -5.96% |
| 2019 FY | 715.95 Thousand USD | 0.0% |
| 2019 Q4 | 178.98 Thousand USD | 0.0% |
| 2019 Q1 | 178.98 Thousand USD | 0.0% |
| 2019 Q2 | 178.98 Thousand USD | 0.0% |
| 2019 Q3 | 178.98 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aspira Women's Health Inc. | 6.26 Million USD | -146.072% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -87.422% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -11.831% |
| Standard BioTools Inc. | 323.06 Million USD | 95.23% |
| Inotiv, Inc. | 856.53 Million USD | 98.201% |
| Prenetics Global Limited | 254.17 Million USD | 93.938% |
| Neuronetics, Inc. | 115.83 Million USD | 86.697% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 82.283% |
| Castle Biosciences, Inc. | 477.81 Million USD | 96.775% |
| Psychemedics Corporation | 13.27 Million USD | -16.119% |
| RadNet, Inc. | 2.88 Billion USD | 99.466% |
| Exact Sciences Corporation | 6.47 Billion USD | 99.762% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 99.527% |
| iSpecimen Inc. | 15.81 Million USD | 2.592% |
| OpGen, Inc. | 1.88 Million USD | -718.639% |
| Exagen Inc. | 56.94 Million USD | 72.94% |
| Bionano Genomics, Inc. | 214.4 Million USD | 92.813% |
| CareDx, Inc | 484.61 Million USD | 96.82% |
| Check-Cap Ltd. | 25.01 Million USD | 38.406% |
| Twist Bioscience Corporation | 776.4 Million USD | 98.015% |
| Guardant Health, Inc. | 1.78 Billion USD | 99.137% |
| Biodesix, Inc. | 99.09 Million USD | 84.45% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -35.169% |
| Precipio, Inc. | 18.1 Million USD | 14.872% |
| Natera, Inc. | 1.45 Billion USD | 98.943% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 98.79% |
| Sera Prognostics, Inc. | 95.44 Million USD | 83.855% |
| 23andMe Holding Co. | 395.16 Million USD | 96.101% |
| OPKO Health, Inc. | 2.01 Billion USD | 99.234% |
| Personalis, Inc. | 225.09 Million USD | 93.155% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 92.194% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -12.874% |
| T2 Biosystems, Inc. | 34.79 Million USD | 55.717% |
| Neogen Corporation | 4.58 Billion USD | 99.664% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 98.715% |
| ICON Public Limited Company | 16.98 Billion USD | 99.909% |
| NeoGenomics, Inc. | 1.68 Billion USD | 99.083% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 82.283% |
| MDxHealth SA | 129.13 Million USD | 88.067% |
| Prenetics Global Limited | 254.17 Million USD | 93.938% |
| Illumina, Inc. | 10.11 Billion USD | 99.848% |
| DarioHealth Corp. | 96.38 Million USD | 84.014% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -128.142% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 99.07% |
| Trinity Biotech plc | 59.43 Million USD | 74.074% |
| Sotera Health Company | 3.13 Billion USD | 99.508% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -87.422% |